Latest Biotech News

A single-nucleus RNA sequencing study identified that physical activity modifies gene expression in Alzheimer’s disease mouse models, notably enhancing responses in microglia and...

The FDA approved UroGen's hydrogel drug Zusduri for low-grade, intermediate-risk, non-muscle invasive bladder cancer despite a narrowly negative advisory committee vote. Clinical trial data...

BioNTech is acquiring CureVac in an all-stock deal valued at $1.25 billion, effectively ending prolonged patent litigation over mRNA vaccine technology. The transaction strengthens BioNTech's...

ADC Therapeutics announced the closure of its U.K. research site, layoffs of 30% of staff, and discontinuation of several preclinical oncology programs after dropping its sole clinical candidate...

The U.S. Food and Drug Administration approved UroGen’s bladder cancer hydrogel, Zusduri, intended for low-grade, intermediate-risk, non-muscle invasive bladder cancer. Approval comes despite a...

BioNTech has agreed to acquire CureVac in a $1.25 billion all-stock transaction, ending years of patent litigation over mRNA vaccine technology. The deal values CureVac’s shares at a 55% premium...

A phase 1 trial combining revumenib, an oral menin inhibitor, with standard azacitidine and venetoclax demonstrated high complete remission rates in patients with acute myeloid leukemia harboring...

Using single-nucleus RNA sequencing, researchers identified that physical activity influences specific hippocampal cell types—microglia and neurovascular-associated astrocytes—in mouse models of...

Researchers developed a method to quickly generate vascular organoids from human induced pluripotent stem cells by simultaneous activation of transcription factors ETV2 and NKX3.1. This technique...

The U.S. FDA authorized Moderna’s mRESVIA respiratory syncytial virus vaccine for use in additional adult populations aged 18 to 59 at risk for RSV infection, broadening availability beyond older...

Scientists at the Technical University of Munich demonstrated that pretraining artificial neural networks with biological data from mouse retinal waves significantly enhances prediction accuracy...

Biopharma continues to experience robust public and private financing in 2025, with new IPOs and funding rounds reported. Key regulatory updates include FDA approvals such as Nuvation Bio’s...

Researchers across six countries conducted the most extensive simultaneous comparison of optical atomic clocks, creating a network spanning thousands of kilometers. This distributed system...

A multidisciplinary team at Harvard's Wyss Institute leveraged AI-enabled molecular modeling and physics-based simulations to identify and optimize bemcentinib derivatives with antiviral activity...

The U.S. Food and Drug Administration granted approval to pembrolizumab as a perioperative treatment for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1. This...

Despite a narrowly negative advisory committee vote, the FDA approved UroGen’s hydrogel formulation for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer based on high...

ADC Therapeutics is closing its UK research facility, discontinuing several preclinical oncology programs, and cutting its workforce by 30% following the termination of its only clinical-stage...

The FDA has approved pembrolizumab, an immune checkpoint inhibitor, for resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, following the pivotal phase 3...

Anne Wojcicki, co-founder and former CEO of 23andMe, secured purchase of the company’s assets for $305 million through her nonprofit, TTAM Research Institute, winning a last-minute auction over...

Following clinical readouts in hypertension, biopharma firm Insmed announced plans for a $750 million follow-on public offering. The move underscores investor confidence after promising trial...